Samsung Electronics
Search results
Samsung Bioepis is a biopharmaceutical company focused on increasing patient access to high-quality medicines through the development of biosimilars. SAMSUNG BIOEPIS Contact Us
Samsung Bioepis is a biopharmaceutical company dedicated to accelerating access to biologic medicines by bringing high-quality, clinically proven biosimilars to patients who need them. Our mission is reflected in our name, bio-epis; literally meaning life (“bio”) and science (“episteme”) in Greek.
Apr 20, 2022 · • Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary. • First payment completed funded through paid in capital. • Accelerated growth expected in biosimilars and future novel therapeutics R&D.
2 days ago · INCHEON, South Korea, July 22, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application ...
2 days ago · About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing health care that is accessible to everyone. Through innovations in ...
Sep 20, 2021 · Pursuant to a global license agreement entered into with Genentech, Samsung Bioepis and Biogen will have freedom to market SB11 in the United States as of June 2022, i.e., before expiration of...
Jul 11, 2024 · About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone.
Jul 11, 2024 · Samsung C&T, a major shareholder of Samsung Biologics which has Samsung Bioepis as a 100% owned subsidiary, has chosen bio/healthcare areas as a sustainable growth engine and the investment in the Flagship Pioneering Fund VIII perfectly matches our mid-term growth strategy,” said Jaywoo Kim, executive vice president, Samsung C&T Corporation.
Aug 17, 2022 · Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology,...
Samsung Bioepis said approximately 70 percent of Soliris-treated PNH patients are not dosed according to the label, which may be attributed to several factors, including the high treatment cost.
